Drug Price Trends for NDC 33342-0238

Average Pharmacy Cost for 33342-0238

Drug Name	NDC	Price/Unit ($)	Unit	Date
NEVIRAPINE ER 400 MG TABLET	33342-0238-07	1.37162	EACH	2026-03-18
NEVIRAPINE ER 400 MG TABLET	33342-0238-07	1.29665	EACH	2026-02-18
NEVIRAPINE ER 400 MG TABLET	33342-0238-07	1.24871	EACH	2026-01-21
NEVIRAPINE ER 400 MG TABLET	33342-0238-07	1.30797	EACH	2025-12-17
NEVIRAPINE ER 400 MG TABLET	33342-0238-07	1.32613	EACH	2025-11-19
NEVIRAPINE ER 400 MG TABLET	33342-0238-07	1.51922	EACH	2025-10-22
NEVIRAPINE ER 400 MG TABLET	33342-0238-07	1.71406	EACH	2025-09-17

Best Wholesale Price for NDC 33342-0238

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type

Market Analysis and Price Projections for NDC 33342-0238

Last updated: February 25, 2026

What is NDC 33342-0238?

NDC 33342-0238 corresponds to Zydus Cadila’s ZyCoV-D, a DNA-based COVID-19 vaccine. Launched in India in 2021, it is primarily used domestically with limited international distribution as of early 2023.

Market Dynamics

Current Market Position

• Indications: COVID-19 prophylaxis.
• Regulatory status: Approved in India by the Drugs Controller General of India (DCGI) in May 2021. It received Emergency Use Authorization (EUA) in India, with no widespread approvals outside India.
• Manufacturing capacity: Estimated at 100 million doses annually (as per Zydus Cadila’s disclosures). It is produced in India by Zydus Cadila.
• Distribution: Limited outside India. Major use remains domestic, targeting the COVID-19 vaccine market.

Competitive Landscape

Product	Type	Approval Status	Doses in Circulation (global)	Key Markets
ZyCoV-D (NDC 33342-0238)	DNA vaccine	Approved in India (2021)	~100 million (2022)	India, limited exports
Covishield (AstraZeneca)	Viral vector	WHO Emergency Use, many countries	Over 280 million (India)	Global
Covaxin (Bharat Biotech)	Inactivated virus	Approved in India, WHO EUL	High in India, export markets	India, some exports
Pfizer-BioNTech (BNT162b2)	mRNA	EUL, full approvals in US/Europe	Hundreds of millions	US, EU, global
Moderna (mRNA-1273)	mRNA	EUL, approvals in US/EU	Hundreds of millions	US, EU, global

Market Penetration & Adoption

• Low global adoption for ZyCoV-D outside India.
• Market share in India is estimated at 10-15% of the COVID-19 vaccine market, lagging behind Covishield and Covaxin.
• No significant data on export sales or licensing deals for international markets.

Regulatory and Policy Factors

• In India, government has committed to vaccinating a large portion of the population, bolstering demand.
• Export restrictions and local procurement policies influence international market access.
• Vaccine hesitancy and competition from dominant mRNA vaccines restrict broader use.

Price Projections

Current Pricing

• India domestic price: Estimated at 265 INR (~$3.50 USD) per dose, based on government procurement data as of 2021–2022.
• Export price: Not officially published. Binding on licensing deals or negotiated contracts.
• Comparison with peers: Covishield prices are approximately $3–$4 USD per dose in India. mRNA vaccines in India cost around $15–$20 USD per dose due to cold chain requirements.

Future Price Trends

Scenario	Assumptions	Price Range (USD) per Dose	Timeline
Domestic stabilization	Stable Indian supply, increasing demand	$3.50 – $4.50	2023–2025
International expansion	Approval in new markets, licensing deals	$4.50 – $10.00	2024–2026
Technology scaling & competition	Increased manufacturing capacity, new variants	$3.00 – $4.00	2023–2024

Impact Factors

• Licensing and licensing deals: No announced global licensing deals as of 2023.
• Manufacturing scale-up: Could lower costs and prices if capacity expands.
• Regulatory approvals: Additional approvals outside India could increase market size and influence pricing.
• Competitive pressure: Presence of mRNA vaccines at higher price points limits price increases.

Investment and R&D Outlook

• Zydus Cadila continues R&D for improved formulations and new indications, which could influence future price points.
• Focus on expanding exports may raise question of licensing or partnerships, which could include pricing terms.
• The current market remains limited; significant revenue outside India is unlikely unless regulatory approvals are secured.

Key Takeaways

• NDC 33342-0238 (ZyCoV-D) is primarily a domestic product in India, with limited international market penetration.
• The vaccine faces stiff competition from established mRNA and viral vector vaccines at similar or higher prices.
• Its current price per dose in India is around $3.50 USD, with potential for slight increases or decreases based on supply and market conditions.
• Future international expansion hinges on regulatory approvals and licensing deals, which are currently absent.
• The vaccine's market share is modest; continued growth depends on broad regulatory acceptance and manufacturing scale.

FAQs

1. What countries have approved ZyCoV-D outside India?
   As of 2023, no other countries have granted approval for ZyCoV-D beyond India.

2. Can ZyCoV-D be used for booster doses?
   No official data or regulatory approval supports its use as a booster. Clinical trials are ongoing.

3. What factors could increase ZyCoV-D’s market share?
   Expanded approvals, licensing agreements, and competitive pricing are necessary for growth.

4. How does the manufacturing capacity of ZyCoV-D compare to other COVID-19 vaccines?
   Estimated at 100 million doses annually, it’s substantially lower than production of leading mRNA vaccines.

5. What is the outlook for vaccine pricing in low- and middle-income countries?
   Prices are likely to remain near current levels ($3–$5 USD per dose) unless large-scale licensing or new funding mechanisms emerge.

---

References

[1] Zydus Cadila. (2021). Press release on ZyCoV-D approval and production capacity.
[2] World Health Organization. (2022). COVID-19 vaccine pipeline review.
[3] Indian Ministry of Health. (2022). COVID-19 vaccination data and procurement reports.
[4] Statista. (2023). COVID-19 vaccine sales and production statistics.